AstraZeneca, Daiichi Sankyo Partner with Summit to Test Datroway-Ivonescimab Combo

AstraZeneca and Daiichi Sankyo will collaborate with Summit Therapeutics to evaluate Datroway combined with ivonescimab in multiple cancer types, including lung and breast. The deal is a clinical-stage collaboration, not a licensing or acquisition, and its financial terms are undisclosed. It signals continued interest in combination immuno-oncology strategies, but market impact is limited until trial data emerges.